KOL Views: Gauging how Biogen's Vumerity will fit into evolving MS landscape

The FDA approved Vumerity (diroximel fumarate) this week based on Phase III data suggesting it offers similar efficacy with better gastrointestinal tolerability relative to Tecfidera (dimethyl fumarate), meaning the race is on for Biogen to transition as many patients over as possible before the latter relapsing multiple sclerosis (MS) drug goes generic.

To provide FirstWord readers with rapid feedback on Vumerity’s commercial prospects, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… to roughly what percentage of patients with relapsing MS do you currently prescribe Tecfidera; how much of a concern have gastrointestinal adverse events been with Tecfidera in your experience; based on available data, would you describe Vumerity as a slight, moderate or significant improvement versus Tecfidera; how much interest is there among physicians for prescribing Vumerity; how high is awareness of Vumerity and have you noticed Biogen begun messaging/promotion; what proportion of patients on Tecfidera do you expect will switch to Vumerity; how quickly will switching take place; will patients on any other MS drugs likely switch to Vumerity; are there patient subgroups that will be ideal early adopters; will any new patients be started on Vumerity; and how much of an impact will Vumerity's price have on prescribing decisions?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the MS treatment paradigm and Vumerity's place in it.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.